Escolar Documentos
Profissional Documentos
Cultura Documentos
33]||ClickheretodownloadfreeAndroidapplicationforthisjournal
Review Article
Keratoconjunctivitis
sicca,
more
commonly
known as dry eye, is an extremely common and
often unrecognized disease. It is the condition in
ophthalmology that in its mild grade of severity will
affect most of the population at one time or other. Due
to a wide variety of presentations and symptoms, it
often frustrates the ophthalmologists as well as patients.
Due to multifactorial and elusive etiology, it is often
challenging to treat dry eye. Ocular surface disorders
are also clinically important to treat especially in terms
of visual acuity. Xero-dacryology is therefore becoming
a very important branch of ophthalmology. Recent
studies have given insight into the inflammatory
etiology of dry eye. The conventional and main
approach to the treatment of dry eye is providing
lubricating eye drops or tear substitutes. However, the
Introduction
Dry eye is one of the most frequently encountered ocular
morbidities, a growing public health problem and one of the
most common conditions seen by eye care practitioners.[1] In
the light of new knowledge about the roles of ocular surface
inflammation and tear hyperosmolarity in dry eye and the effects
of dry eye on visual function, the International Dry Eye Workshop
(DEWS) defined dry eye as a multifactorial disease of the tears
Access this article online
Quick Response Code:
Website:
www.ojoonline.org
DOI:
10.4103/0974-620X.83653
Copyright: 2011 Bhavsar AS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Correspondence:
Dr. Sunita M. Jain, Department of Pharmacology, L. M. College of Pharmacy, Navrangpura, Ahmedabad 380009, Gujarat, India.
E-mail: sunitalmcp@yahoo.com
50
[Downloadedfreefromhttp://www.ojoonline.orgonFriday,August22,2014,IP:223.255.230.33]||ClickheretodownloadfreeAndroidapplicationforthisjournal
51
[Downloadedfreefromhttp://www.ojoonline.orgonFriday,August22,2014,IP:223.255.230.33]||ClickheretodownloadfreeAndroidapplicationforthisjournal
52
[Downloadedfreefromhttp://www.ojoonline.orgonFriday,August22,2014,IP:223.255.230.33]||ClickheretodownloadfreeAndroidapplicationforthisjournal
Treatment Approaches
As evident from pathophysiology of dry eye, many factors
contribute to or exacerbate dry eye, including: tear deficiency, tear
instability, irritation and inflammation. Over the past few years, as
a result of numerous studies, new concepts of pathogenesis have
shown that DED seems to be inflammatory in origin, mediated by
Tcell lymphocytes.[3,5] This finding has also been augmented by
the studies investigating the role of anti-inflammatory therapies.
So, in the last few years, there has been a paradigm shift in the
strategy to treat DED. However, conventional treatment still has
importance. Therapy of dry eye requires a multipronged approach
Oman Journal of Ophthalmology, Vol. 4, No. 2, 2011
Tear substitutes
Still they are the mainstay of treatment for mild to moderate aqueous
tear deficiency. They are aqueous solutions containing polymers
that determine their viscosity, retention time and adhesion to
ocular surface such as cellulose derivatives [e.g. hydroxypropyl
methyl cellulose (HPMC), carboxymethyl cellulose], polyvinyl
derivatives (e.g. polyvinyl alcohol), chondroitin sulfate, and
sodium hyluronate.[53]
Artificial tears provide temporary improvement in symptoms of
eye irritation, blurred vision and visual contrast sensitivity.[54]
Artificial tears containing preservatives, particularly benzylkonium
chloride, are poorly tolerated and harmful in moderate to severe
cases, especially if used frequently.
Antiinflammatory therapy
Due to a newer understanding of the pathogenesis of DED, use of
antiinflammatory medications is a paradigm shift in the treatment
of dry eye. It addresses the root cause of the dry eye instead of
giving symptomatic relief as done by lubricants. Antiinflammatory
therapy is considered to be the first causative therapeutic
approach in the treatment of dry eye, since its objective is to
interrupt the inflammatory cascade.[24,55]
In this section of the review, we present uptodate antiinflammatory
therapy strategies discussing both well-known and newly designed
current novel medications.
1 Cyclosporine A (CsA): Several clinical studies have shown
topical CsA to improve both objective and subjective sign
of KCS.[56-59] It is a fungal derived peptide that prevents Tcell
activation and inflammatory cytokine production.[60] It also
inhibits mitochondrial mediated pathways of apoptosis.
Recently, several large multicentric randomized trials
confirmed the safety and efficacy of topical application of CsA
for the treatment of dry eyes. It marks the first step in shifting
focus of the therapy into the underlying mechanisms that
53
[Downloadedfreefromhttp://www.ojoonline.orgonFriday,August22,2014,IP:223.255.230.33]||ClickheretodownloadfreeAndroidapplicationforthisjournal
Secretagogues
They are cholinergic agonists that stimulate endogenous tear
production by the lacrimal glands and/or ocular surface epithelia
(e.g. oral pilocarpine).[73] The main limitation is systemic
cholinergic side effects like sweating, nausea and intestinal
cramping.[25] Recently, a muscarinic acetylcholine receptor agonist,
cevimeline, has been approved for use against symptoms of dry
mouth in patients with Sjogren syndrome. It has been found that
54
Surgical treatment
In patients who continue to have significant pathology despite
medical therapy, surgical treatment may be considered in a
stepwise fashion.[25]
1 Punctal occlusion: One of the most useful and practical
therapies for conserving tears. Purpose is to decrease
physiological outflow of the tear film down the nasolacrimal
system.
2 Tarsorrhaphy and botulinum toxin induced ptosis: They
decrease the palpebral aperture height, thus decreasing tear
evaporation.
3 Salivary gland transplantation: Reported to be successful in
patients with severe lacrimal gland dysfunction with intact
salivary function (e.g. Sjogren syndrome), radiation-induced
lacrimal gland atrophy or surgical removal of lacrimal
gland. Though the results appear to be promising, there is
disadvantage of technical complexity and altered tear film
consistency and composition and possibility of tear secretion
during eating (i.e. crocodile tears).
In conclusion, the therapy of dry eye traditionally involved
hydrating and lubricating the ocular surface, which may provide
temporary improvement in symptoms of irritation and blurred
vision, but did not address the inflammation that is the underlying
cause of dry eye. New insights into the inflammatory nature of this
disease have led to a paradigm shift in the therapeutic approach
to KCS. In particular, treatment is now directed more toward
suppressing the inflammatory response on the ocular surface.
References
1.
2.
3.
4.
5.
OBrien PD, Collum LM. Dry eye: Diagnosis and current treatment
strategies. Curr Allergy Asthma Rep 2004;4:314-9.
The definition and classification of dry eye disease: Report of the Definition
and Classification Subcommittee of the International Dry Eye Workshop
(2007). Ocul Surf 2007;5:75-92.
Gao J, Schwalb TA, Addeo JV, Ghosn CR, Stern ME. The role of apoptosis
in the pathogenesis of canine keratoconjunctivitis sicca: The effect of
topical cyclosporine A therapy. Cornea 1998;17:654-63.
Kunert KS, Tisdale AS, Stern ME, Smith JA, Gipson IK. Analysis of topical
cyclosporine treatment of patients with dry eye syndrome: Effect on
conjunctival lymphocytes. Arch Ophthalmol 2000;118:1489-96.
Stern ME, Gao J, Schwalb TA, Ngo M, Tieu DD, Chan CC, et al. Conjunctival
T-cell subpopulations in Sjgrens and non- Sjgrens patients with dry
eye. Invest Ophthalmol Vis Sci 2002;43:2609-14.
[Downloadedfreefromhttp://www.ojoonline.orgonFriday,August22,2014,IP:223.255.230.33]||ClickheretodownloadfreeAndroidapplicationforthisjournal
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Pflugfelder SC. The Lacrimal Functional Unit. In: Pflugflelder SC, Roger
WB, editors. Dry eye and Ocular Surface disorders. New York: Marcel
Dekker; 2004. p. 11-32.
Gayton JL. Etiology, prevalence and treatment of dry eye disease. Clin
Ophthalmol 2009;3:405-12.
Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pflugfelder SC. A
unified theory of the role of the ocular surface in dry eye. Adv Exp Med
Biol 1998;438:643-51.
The epidemiology of dry eye disease: Report of the Epidemiology
Subcommittee of the International Dry Eye Workshop (2007). Ocul Surf
2007;5:93-107.
Lambert DW, Foster CS, Perry HD. Schirmer test after topical anesthesia
and the tear meniscus height in normal eyes. Arch Ophthalmol
1979;97:1082-5.
Connor CG, Flockencier LL, Hall CW. The influence of gender on the
ocular surface. J Am Optom Assoc 1999;70:182-6.
Krenzer KL, Dana MR, Ullman MD, Cermak JM, Tolls DB, Evans JE, et al.
Effect of androgen deficiency on the human meibomian gland and ocular
surface. J Clin Endocrinol Metab 2000;85:4874-82.
Schaumberg DA, Buring JE, Sullivan DA. Hormone replacement therapy
and dry eye syndrome. JAMA 2001;286:21149.
Ang RT, Dartt DA, Tsubota K. Dry eye after refractive surgery. Curr Opin
Ophthalmol 2001;12:318-22.
Donnenfeld ED, Ehrenhaus M, Solomon R, Mazurek J, Rozell JC, Perry
HD. Effect of hinge width on corneal sensation and dry eye after laser
in situ keratomileusis. J Cataract Refract Surg 2004;30:790-7.
Lee AJ, Lee J, Saw SM, Gazzard G, Koh D, Widjaja D, et al. Prevalence
and risk factors associated with dry eye symptoms: A population based
study in Indonesia. Br J Ophthalmol 2002;86:1347-51.
Schlote T, Kadner G, Frudenthaler N. Marked reduction and distinct
pattern of eye blinking in patients with moderately dry eyes during video
display terminal use. Graefes Arch Clin Exp Ophthalmol 2004;242:306-12.
Blehm C, Vishnu S, Khattak A, Mitra S, Yee RW. Computer vision
syndrome: A review. Surv Ophthalmol 2005;50:253-62.
Wolkoff P, Njaard JK, Troiano P, Piccoli B. Eye complaints in the office
environment: Precorneal tear film integrity influenced by eye blinking
efficiency. Occup Environ Med 2005;62:4-12.
Wolkoff P, Njaard JK, Franck C, Skov P. The modern office environments
desiccate the eye? Indoor Air 2006;16:258-65.
Management and therapy of dry eye disease: Report of the Management
and Therapy Subcommittee of the International Dry Eye WorkShop
(2007). Ocul Surf 2007;5:163-78.
Corrales RM, Villarreal A, Farley W, Stern ME, Li DQ, Pflugfelder SC.
Strain-related cytokine profiles on the murine ocular surface in response
to desiccating stress. Cornea 2007;26:579-84.
Li DQ, Pflugfelder SC. Matrix metalloproteinases in corneal inflammation.
Ocul Surf 2005;3(4 Suppl):S198-202.
Gumus K, Cavanagh DH. The role of inflammation and antiinflammation
therapies in keratoconjunctivitis sicca. Clin Ophthalmol 2009;3:57-67.
Djalilian AR, Pedram H, Pflugfelder SC. Dry Eye. In: Krachmer, Mannis,
Holland, editors. Cornea, Vol 1, 2nd ed. Philadeiphia: Elsevier; 2005. p.
521-38.
Dana MR, Hamarah P. Role of immunity and inflammation in corneal
and ocular surface disease associated with dry eye. Adv Exp Med Biol
2002;506:729-38.
Hamarah P, Haq SO, Gulati A, Dana MR. Mechanism of ocular surface
immune response. In: Pflugflelder SC, Roger W.B, editors. Dry eye and
Ocular Surface disorders. New York: Marcel Dekker; 2004. p. 111-41.
Zoukhri D. Effect of inflammation on lacrimal gland function. Exp Eye Res
2006;82:885-98.
Zhu Z, Stevenson D, Ritter T, Schechter JE, Mircheff AK, Kaslow HR,
et al. Expression of IL-10 and TNF-inhibitor genes in lacrimal gland
epithelial cells suppresses their ability to activate lymphocytes. Cornea
2002;21:210-4.
Brignole F, De Saint Jean M, Goldschild M, Becquet F, Goguel A,
Baudouin C. Expression of the fas-fas ligand antigens and appropriate
marker apo2.7 by the human conjunctival epithelium. Positive correlation
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
55
[Downloadedfreefromhttp://www.ojoonline.orgonFriday,August22,2014,IP:223.255.230.33]||ClickheretodownloadfreeAndroidapplicationforthisjournal
68. Roncone M, Bartlett H, Eperjesi F. Essential fatty acids for dry eye: A
review. Cont Lens Anterior Eye 2010; 33 Suppl 2:49-54; quiz 100.
69. Hayashi Y, Ishimaru N, Arakaki R, Tsukumo S, Fukui H, Kishihara K, et
al. Effective treatment of a mouse model of Sjgrens syndrome with
eyedrop administration of anti-CD4 monoclonal antibody. Arthritis Rheum
2004;50:2903-10.
70. Fox RI, Dixon R, Guarrasi V, Krubel S. Treatment of primary Sjgrens
syndrome with hydroxychloroquine: A retrospective, open-label study.
Lupus 1996;5 Suppl 1:S31-6.
71. Yavuz S, Asfurolu E, Bicakcigil M, Toker E. Hydroxychloroquine improves
dry eye symptoms of patients with primary Sjogrens syndrome. Rheumatol
Int 2010 [In press].
72. Seo MJ, Kim JM, Lee MJ, Sohn YS, Kang KK, Yoo M. The therapeutic
effect of DA-6034 on ocular inflammation via suppression of MMP-9 and
inflammatory cytokines and activation of the MAPK signaling pathway in
an exp erimental dry eye model. Curr Eye Res 2010;35 Suppl 2:165-75.
73. Garg A. In: Garg A, editor. Clinical diagnosis and management of dry
eye and ocular surface disorders (Xero-Decryology). New Delhi: Jaypee;
2006. p. 99.
74. Ono M, Takamura E, Shinozaki K, Tsumura T, Hamano T, Yagi Y, Tsubota
K. Therapeutic effect of cevimeline on dry eye in patients with Sjgrens
syndrome: A randomized, double-blind clinical study. Am J Ophthalmol
2004;138 Suppl 1:6-17.
75. Avni I, Garzozi HJ, Barequet IS, Segev F, Varssano D, Sartani G, et al.
Treatment of Dry Eye Syndrome with Orally Administered CF101 Data
from a Phase 2 Clinical Trial. Ophthalmology 2010;117:1287-93.
76. Lee MS, Shin BC, Choi TY, Ernst E. Acupuncture for treating dry eye: A
systematic review. Acta Ophthalmol 2011;89:101-6.
Cite this article as: Bhavsar AS, Bhavsar SG, Jain SM. A review on recent
advances in dry eye: Pathogenesis and management. Oman J Ophthalmol
2011;4:50-6.
Source of Support: Nil, Conflict of Interest: None declared.
Announcement
Android App
A free application to browse and search the journals content is now available for Android based
mobiles and devices. The application provides Table of Contents of the latest issues, which
are stored on the device for future offline browsing. Internet connection is required to access the
back issues and search facility. The application is compatible with all the versions of Android. The
application can be downloaded from https://market.android.com/details?id=comm.app.medknow.
For suggestions and comments do write back to us.
56